Loading organizations...

§ Private Profile · Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland
HAYA Therapeutics SA is a company.
HAYA Therapeutics SA has raised $95.0M across 4 funding rounds.
Key people at HAYA Therapeutics SA.
HAYA Therapeutics SA has raised $95.0M in total across 4 funding rounds.
HAYA Therapeutics SA develops precise and potent RNA-guided programmable therapeutics by leveraging the power of the regulatory "dark genome." The company's technology decodes complex disease causality, targeting regulatory RNAs to address conditions driven by cell-state reprogramming. This platform allows for repeatable drug discovery, with lead programs focusing on fibrotic, metabolic, and age-related diseases.
The company was co-founded in 2017 by Daniel Blessing and Samir Ounzain, with Dr. Ounzain serving as CEO and Scientific Co-Founder. His extensive background as a molecular biologist, exploring the regulatory "dark matter" of the human genome for over two decades, provided the foundational insights. This deep scientific understanding informed HAYA's approach to unlock novel therapeutic pathways.
HAYA Therapeutics aims to serve patients afflicted with serious fibrotic, metabolic, and age-related health conditions. Their vision is to advance programmable therapeutics derived from regulatory RNAs, ultimately developing innovative precision medicines that profoundly impact disease progression and improve patient outcomes.
HAYA Therapeutics SA is a precision medicines company developing programmable RNA-guided therapeutics that target long non‑coding RNAs (lncRNAs) in the regulatory “dark” genome to treat fibrotic, metabolic, cardiovascular and age‑related diseases, with a lead program for heart failure and a platform designed for tissue‑ and cell‑selective reprogramming of pathological cell states[3][7].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Biotech Landscape
Quick Take & Future Outlook
HAYA Therapeutics SA has raised $95.0M across 4 funding rounds. Most recently, it raised $65.0M HAYA Therapeutics - Series A in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $65M Series A | Soffinova Partners, Earlybird Venture Capital | AbbVie Ventures, Apollo Health Ventures, Broadview Ventures, Humboldt Fund, 4See Ventures, Alexandria Venture Investments, Athos, BERNINA BioInvest, Benjamin Kreitman, ELI Lilly And Company, Lifelink, NanoDimension, Schroders Capital | Announced |
| Feb 10, 2022 | $5M Seed Plus | Humboldt Fund | 4See Ventures, Apollo Health Ventures, BERNINA BioInvest, Broadview Ventures, Schroder Adveq | Announced |
| Feb 1, 2022 | $5M Seed | — | Apollo Health Ventures, Broadview Ventures, Humboldt Fund, Soffinova Partners | Announced |
| May 1, 2021 | $20M Seed | Benjamin Kreitman | Apollo Health Ventures, Broadview Ventures, Humboldt Fund, Soffinova Partners, 4See Ventures, BERNINA BioInvest, Schroder Adveq | Announced |
HAYA Therapeutics SA has raised $95.0M in total across 4 funding rounds.
HAYA Therapeutics SA's investors include Soffinova Partners, Earlybird Venture Capital, AbbVie Ventures, Apollo Health Ventures, Broadview Ventures, Humboldt Fund, 4See Ventures, Alexandria Venture Investments, ATHOS, BERNINA BioInvest, Benjamin Kreitman, Eli Lilly and Company.
Key people at HAYA Therapeutics SA.